Table 1 General characteristics
Total group (n = 174) | HFpEF (n = 37) | HFmrEF (n = 62) | HFrEF (n = 75) | p value | |
|---|---|---|---|---|---|
Baseline demographics | |||||
Age—yr | 68 [59–75] | 74 [70–80] | 62 [56–68] | 68 [60–76] | < 0.01 |
Male | 120 [69%] | 18 [49%] | 42 [68%] | 60 [80%] | < 0.01 |
Body mass index—kg/m2 | 26 [24–29] | 28 [26–31] | 26 [24–28] | 26 [24–29] | 0.03 |
Hypertension | 88 [51%] | 28 [76%] | 28 [45%] | 32 [43%] | < 0.01 |
Systolic blood pressure—mmHg | 132 [118–145] | 142 [132–164] | 131 [120–141] | 129 [116–141] | < 0.01 |
Diastolic blood pressure—mmHg | 76 [71–85] | 79 [70–88] | 79 [72–86] | 74 [71–80] | 0.13 |
Heart Rate—bpm | 66 [58–78] | 68 [60–82] | 69 [59–75] | 65 [57–80] | 0.76 |
Diabetes Mellitus | 26 [15%] | 3 [8%] | 8 [13%] | 15 [20%] | 0.23 |
COPD | 21 [12%] | 8 [22%] | 6 [10%] | 7 [9%] | 0.14 |
Chronic kidney disease | 21 [12%] | 6 [16%] | 4 [6%] | 11 [15%] | 0.23 |
Coronary artery disease | 67 [39%] | 6 [16%] | 23 [37%] | 38 [51%] | < 0.01 |
NYHA functional class | |||||
I | 61 [37%] | 8 [24%] | 33 [54%] | 20 [28%] | < 0.01 |
II | 62 [37%] | 13 [38%] | 17 [28%] | 32 [44%] | 0.14 |
III | 40 [24%] | 11 [32%] | 9 [15%] | 20 [28%] | 0.09 |
IV | 4 [2%] | 2 [6%] | 2 [3%] | 0 [0%] | 0.08 |
Heart failure medication | |||||
Beta-blocker | 137 [79%] | 26 [70%] | 50 [81%] | 61 [82%] | 0.31 |
Renin-angiotensin system antagonist | 137 [79%] | 26 [70%] | 52 [84%] | 59 [80%] | 0.27 |
Mineralocorticoid antagonist | 54 [31%] | 6 [16%] | 19 [31%] | 29 [39%] | 0.05 |
Neprilysine Inhibitor | 5 [3%] | 0 [0%] | 2 [3%] | 3 [4%] | 0.72 |
Loop diuretics | 71 [41%] | 17 [46%] | 16 [26%] | 38 [51%] | 0.01 |
Endpoints | |||||
Heart Failure Hospitalization | 18 [10%] | 3 [8%] | 3 [5%] | 12 [16%] | 0.09 |
Mortality | 11 [6%] | 3 [8%] | 1 [2%] | 7 [9%] | 0.12 |
Composite endpoint | 23 [13%] | 4 [11%] | 3 [5%] | 16 [21%] | 0.02 |